



Non-antiviral Agents for Treatment of COVID-19 2.0

Guest Editor:

Dr. Toshihiro Kita

Frontier Science Research Center,
University of Miyazaki, Miyazaki,
Japan

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editor

Dear Colleagues,

The novel coronavirus disease (COVID-19) continues to affect millions around the world, with no end in sight. A significant number of patients with COVID-19 who experienced exacerbated symptoms have died. Thus, saving the lives of patients with severe COVID-19 is currently of the highest importance. While antiviral agents, including those currently under development, are effective in the early phase of the disease, they are not effective in the late and advanced phases of COVID-19. Alternative approaches are required for these cases, including modulators for cytokines, inflammation inhibitors, and protective agents for tissue injury. This Special Issue aims to publish original research papers and/or relevant reviews of the most recent literature on the beneficial effects of non-antiviral agents for the treatment of moderate-to-severe COVID-19.

Dr. Toshihiro Kita

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI